{"disease":{"id":"pirtobrutinib","name":"pirtobrutinib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07416890","title":"Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}